BVBarbora Vakrmanova

Barbora Vakrmanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Barbora Vakrmanova has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Starý

    Department of Pediatric Hematology and Oncology Motol University Hospital Prague Czech Republic

    24 shared publications
  • Ales Luks

    Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic

    1 shared publication
  • Alexandra Kolenova

    Comenius University Children's Hospital, Bratislava, Slovakia

    1 shared publication
  • Anja Möricke

    University Medical Center, Christian Albrechts University Kiel, Kiel, Germany

    1 shared publication
  • Anthony V. Moorman

    Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle upon Tyne, UK

    1 shared publication
  • Antonis Kattamis

    First Department of Pediatrics, University of Athens, Athens, Greece

    1 shared publication

Latest Publications

  • CD38: A target in relapsed/refractory acute lymphoblastic leukemia—Limitations in treatment and diagnostics

    by Barbora Vakrmanová, Michaela Nováková, Petr Říha, Markéta Žaliová, Eva Froňková, Ester Mejstříková, Jan Starý, Ondřej Hrušák, Lucie Šrámková

    Daratumumab, an anti‐CD38 antibody, is used experimentally in the treatment of relapsed acute lymphoblastic leukemia (ALL). We treated five patients suffering from relapsed ALL with daratumumab. Four patients had T ALL, three of whom achieved complete remission (CR) after treatment and underwent stem cell transplant (SCT). Two of them had a second relapse and died 6 and 8 months after SCT, respectively. One transplanted T ALL patient remained in CR2 15 months after relapse. In the remaining T‐ALL patient, the disease progressed under daratumumab treatment, and the patient died early after the first relapse. The B‐cell precursor ALL patient with a second CD19‐negative relapse, whose disease turned out to be resistant to the combination of daratumumab with chemotherapy, later achieved CR3 with inotuzumab ozogamicin, underwent SCT and remained in CR3. Leukemia burden should be monitored after daratumumab, and care should be taken not to misclassify leukemic cells with false negativity of surface CD38; using an antibody reacting with nondaratumumab epitopes is advantageous.


  • Faculty Opinions recommendation of IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.

    by Jan Starý, Barbora Vakrmanova

    The prognosis of T cell acute lymphoblastic leukemia (T-ALL) has improved recently, especially in pediatric patients with almost 85% survival. However, this disease has still dismal prognosis when relapsed. In BCP-ALL, the stratification algorithm is based on minimal residual disease assessment as well as genetic background of leukemia, for example IKZF1Alt, which is included in high-risk stratification criteria. Such a stratification based on genetics is missing in T-ALL. In this article, Dr. Simonin and his team described IKZF1Alt among 1,260 adults and children with T-ALL with frequency 6.5%. They also confirmed poor prognosis in IKZF1Alt T-ALL compared to IKZF1WT suggesting a high-risk stratification for IKZF1Alt T-ALL, which can decrease relapse rate and thus improve prognosis in this genetic subtype.

  • Faculty Opinions recommendation of Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL.

    by Jan Starý, Barbora Vakrmanova

    Blinatumomab, a bi-specific T-cell engager monoclonal antibody against CD19, has shown promising results in relapsed/refractory B cell precursor acute lymphoblastic leukemias (BCP ALL) and is now tested in frontline protocols as well. In BCR-ABL1 positive patients, blinatumomab was approved for relapsed cases. However, efficacy of blinatumomab in patients with BCR-ABL1 fusion gene is still poorly explored. One mechanism on resistance may be caused by preexisting BCR-ABL1 positive clone in CD19-negative cells {1-2}. In this article, Dr. Leonard and her team explore another possible mechanism of resistance. According to their data, both dasatinib and ponatinib decrease efficacy of blinatumomab in vitro if used concomitantly. Those dual ABL/Src kinase inhibitors decrease proliferation of T cells and secretion of IFN-gamma in healthy donors and BCR-ABL1+ALL samples by inhibition of tyrosine kinase LCK. The addition of imatinib and nilotinib (ABL specific inhibitors with no effect on Src kinase) did not affect blinatumomab efficacy. Although the data are limited and clinical study would be needed to prove their theory, the possible interaction of those dual ABL/Src kinase inhibitors with blinatumomab should be taken into consideration in therapy of relapsed BCR-ABL1+ ALL.

  • Faculty Opinions recommendation of Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: A report from the children's oncology group.

    by Jan Starý, Barbora Vakrmanova

    Asparaginase is an integral component of acute lymphoblastic leukemia (ALL) treatment in pediatric protocols. In high-income counties, pegylated asparaginase derived from the bacterium E. coli is used as first-line therapy. However, the drug is associated with many adverse effects such as hypersensitivity reaction, pancreatitis, thrombosis or hepatotoxicity, which might lead to omitting some doses required in the protocol. Erwinia chrysanthemi asparaginase can be used as a substitute for patients who develop hypersensitivity reaction on pegylated E. coli asparaginase. In this study, Gupta and his team compared the outcome of over 8000 patients who A) received all asparaginase doses according to the protocol, versus B) patients who switched to Erwinia asparaginase, versus C) patients who didn’t receive all asparaginase doses. According to their data, high risk and slow early response patients who didn’t receive all asparaginase doses had worse outcome compared to patients on E. coli or Erwinia asparaginase. Considering the size of the cohort, this is the largest study focusing on the impact of asparaginase discontinuation on the outcome among children with B-cell ALL.

  • Faculty Opinions recommendation of JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.

    by Jan Starý, Barbora Vakrmanova

    Cytokine storm syndromes (CSS) are severe hyperinflammatory conditions characterized by excessive immune system activation leading to organ damage and death. Hemophagocytic lymphohistiocytosis (HLH), a disease often associated with inherited defects in cell-mediated cytotoxicity, serves as a prototypical CSS for which the five-year survival is only 60%. Frontline therapy for HLH consists of the glucocorticoid dexamethasone (DEX) and the chemotherapeutic agent etoposide. Many patients, however, are refractory to this treatment or relapse after an initial response. Notably, many cytokines that are elevated in HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in murine HLH models and humans with refractory disease. We recently reported that cytokine-induced JAK/STAT signaling mediates DEX resistance in T cell acute lymphoblastic leukemia (T-ALL) cells, and that this could be effectively reversed by RUX. Based on these findings, we hypothesized that cytokine-mediated JAK/STAT signaling might similarly contribute to DEX resistance in HLH and that RUX treatment would overcome this phenomenon. Using ex vivo assays, a murine model of HLH, and primary patient samples, we demonstrate that the hypercytokinemia of HLH reduces the apoptotic potential of CD8 T cells leading to relative DEX resistance. Upon exposure to RUX, this apoptotic potential is restored, thereby sensitizing CD8 T cells to DEX-induced apoptosis in vitro and significantly reducing tissue immunopathology and HLH disease manifestations in vivo. Our findings provide rationale for combining DEX and RUX to enhance the lymphotoxic effects of DEX and thus improve the outcomes for patients with HLH and related CSS. Copyright © 2020 American Society of Hematology.


  • Faculty Opinions recommendation of Ruxolitinib for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis.

    by Jan Starý, Barbora Vakrmanova

    Hemophagocytic lymphohistiocytosis (HLH) is a heterogenic group of diseases caused by uncontrolled activation of the immune system with a dismal outcome. Wang and colleagues collected data from a cohort of 34 patients with refractory/relapsed secondary HLH and treated them with ruxolitinib, a JAK/STAT pathway inhibitor. Even though the study was not randomized, the results are promising with an overall response 74%. The prognosis seemed to be worse within EBV-HLH patients, especially if they didn’t receive HSCT. In patients with ruxolitinib response, the levels of proinflammatory cytokines were significantly decreased, explaining the mechanism of ruxolitinib effect. Ruxolitinib seems to be a safe therapeutic option for patients nonresponding to conventional therapy and should be considered to be added to frontline therapy for HLH.


  • Faculty Opinions recommendation of Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation.

    by Jan Starý, Barbora Vakrmanova

    Development of clonal hematopoiesis (increasing with age) is associated with a higher risk of hematological malignancies. The preexistence of clonal hematopoiesis in healthy bone marrow donors is not routinely tested. The team provided retrospective screening of 42 donors and their recipients for the presence of clonal hematopoiesis by NGS sequencing. The clonal hematopoiesis was highly prevalent (24% and 31% in donor and recipients, respectively). Five of these cases were donor-engrafted with one progressing into myelodysplastic syndrome in both donor and recipient. Moreover, the team investigated the character of clonal hematopoiesis with more than one mutation (sub-clonality versus more independent clones) and the presence of cones in different cell subtypes. How often donor-engrafted clonal hematopoiesis progresses into myeloid malignancy (and what the impact on the outcome is) still remains to be determined on a larger cohort, but the results provide interesting new information about clonal hematopoiesis and its behavior during hematopoietic stem cell transplantation.


  • Faculty Opinions recommendation of Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia.

    by Jan Starý, Barbora Vakrmanova

    Chimeric antigen receptor (CAR) T cells have radically improved the treatment of B cell-derived malignancies by targeting CD19. The success has not yet expanded to treat acute myeloid leukemia (AML). We developed a Sequentially Tumor-selected Antibody and antigen Retrieval (STAR) system to rapidly isolate multiple nanobodies (Nbs) that both preferentially bind AML cells and empower CAR T cells with anti-AML efficacy. The STAR-isolated Nb157 specifically bound CD13, which is highly expressed in AML cells, and CD13 CAR T cells potently eliminated AML in vitro and in vivo. CAR T cells bi-specific for CD13 and TIM3, which is upregulated in AML leukemia stem cells, eradicated patient-derived AML, with much reduced toxicity to human bone marrow stem cells and peripheral myeloid cells in mouse models, highlighting a promising approach for developing effective AML CAR T therapy. Copyright © 2020 American Society of Hematology.

  • Faculty Opinions recommendation of Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study.

    by Jan Starý, Barbora Vakrmanova

    Allogeneic hematopoietic stem cell transplantation is the treatment of choice in patients with high risk acute myeloid leukemia (AML). The absence of HLA-matched sibling donor (MSD) is one of the main limitations of transplantation. Recently, this problem was partially solved with transplantation from haploidentical donor (HID). There has been no consensus regarding relapse rate, survival and transplantation toxicity comparing these two approaches due to the heterogeneity of previous studies and lack of randomization. Yu and his team enrolled 189 patients with high risk AML transplanted either from MSD or HID into a multicentric prospective study. Patients were randomized according to absence of MSD (biological randomization). The primary endpoint was the incidence of posttransplant minimal residual disease (MRD) positivity. They proved lower MRD positivity in HID compared to MSD, suggesting superior graft-versus-leukemia effect even though the relapse-free survival didn’t differ between these two groups. Severe graft-versus-host disease (GVHD) was similar between both groups. According to these results, HID transplantation seems to be equally as good as MSD transplantation.


  • Faculty Opinions recommendation of Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.

    by Jan Starý, Barbora Vakrmanova

    Low chemosensitivity is the main reason for poor prognosis of relapsed acute lymphoblastic leukemias in children. In this study, the team tried to elucidate the genetic background of chemoresistance in relapses. By comparing 103 diagnosis-relapse samples pairs they identify genes with relapsed-specific mutation involved in drug metabolism. Next, they compared 208 samples from 16 patients taken during the time from diagnosis to relapse. By this approach, they could track the first appearance of resistant clone during therapy and determine if the relapse is due to pre-existing clone at diagnosis (observed in very early relapses) or due to acquired chemoresistance during treatment (observed in early and late relapses). These findings suggest that chemoresistance in relapses could be preventable by altered front-line treatment strategies.